CP Weesp, Netherlands

Hendrikus T Rigter


Average Co-Inventor Count = 9.3

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Weesp, NL (2008)
  • CP Weesp, NL (2011)

Company Filing History:


Years Active: 2008-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hendrikus T Rigter: Innovator in Pharmaceutical Science

Introduction

Hendrikus T Rigter is a notable inventor based in CP Weesp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel dosage forms and compounds. With a total of 2 patents, his work focuses on improving treatment options for various diseases and disorders.

Latest Patents

Rigter's latest patents include innovative pharmaceutical dosage forms aimed at maintenance treatment. One of his key inventions is the "Bifeprunox mesylate maintenance dose compositions and methods for using the same." This patent provides novel pharmaceutical dosage forms and methods for utilizing these compounds to treat and prevent diseases. Another significant patent is for a "Stable crystalline form of bifeprunox mesylate," which relates to a stable polymorphic form of the compound 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate. This invention is particularly relevant for pharmaceutical products aimed at treating psychotic disorders and Parkinson's disease.

Career Highlights

Hendrikus T Rigter is associated with Solvay Pharmaceuticals B.V., where he has been instrumental in advancing pharmaceutical research and development. His expertise in creating stable pharmaceutical formulations has positioned him as a valuable asset in the industry.

Collaborations

Rigter has collaborated with notable colleagues such as Irene Eijgendaal and Gerrit Klein. These partnerships have contributed to the successful development of his innovative pharmaceutical solutions.

Conclusion

Hendrikus T Rigter's contributions to pharmaceutical science through his patents and collaborations highlight his commitment to improving treatment options for patients. His work continues to influence the field and pave the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…